Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2018

01-04-2018 | Melanomas

Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China

Authors: Siming Li, MD, Xinan Sheng, MD, Lu Si, MD, Chuanliang Cui, MD, Yan Kong, PhD, Lili Mao, MD, Bin Lian, MD, Bixia Tang, MD, Xieqiao Yan, MD, Xuan Wang, MD, Zhihong Chi, MD, Jun Guo, MD

Published in: Annals of Surgical Oncology | Issue 4/2018

Login to get access

Abstract

Purpose

This study was designed to evaluate the efficacy of isolated limb infusion (ILI) treatment in Chinese patients with in-transit melanoma and to identify factors predictive of the outcome.

Methods

A total of 150 patients with in-transit melanoma who received a single ILI between 2007 and 2016 were identified from a prospectively collected database.

Results

All patients had AJCC Stages IIIb, IIIc, and IV disease. Acral lentiginous melanoma (ALM) accounted for 79% of patients, and 59% had a high burden of disease (BOD). The complete response (CR) and partial response (PR) rates were 6 and 35%, respectively. Forty-five percent of patients experienced grade III–IV limb toxicities, but no grade V toxicity was observed. Patients with a low BOD, high limb temperature, high peak creatine phosphokinase (CK) level, and grade III–IV limb toxicity achieved higher response rates. Stage IV disease and high BOD were associated with worse infield progression-free survival (PFS) and overall survival (OS), whereas patients with CR or PR to ILI had better infield PFS and OS. Multivariate analyses showed that disease stage, BOD, and a CR were independent predictors of infield PFS, whereas disease stage and a response to ILI were independent predictors of OS.

Conclusions

ILI is well-tolerated but the response rate in Chinese patients was lower than that reported in US and Australian studies. The prevalence of the ALM histological type, advanced disease stages, and a high BOD may be the main reasons for this. A response to ILI, BOD, and disease stage are prognostic factors for survival.
Literature
1.
Coit DG, Ferrone CR. Recurrent regional metastases of melanoma. In: Balch CM, Houghton AN, Sober AJ, Soong SJ, Atkins MB, Thompson JF (eds) Cutaneous melanoma, 5th edn. St. Louis: Quality Medical Publishing, 2009:487–98.
2.
3.
Weide B, Neri D, Elia G. Intralesional treatment of metastatic melanoma: a review of therapeutic options. Cancer Immunol Immunother. 2017;66(5):647–56.CrossRefPubMed
4.
Agarwala SS. The role of intralesional therapies in melanoma. Oncology (Williston Park). 2016;30(5):436–41.
5.
Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–88.CrossRefPubMed
6.
Creech O, Jr., Krementz ET, Ryan RF, et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg. 1958;148(4):616–32.CrossRefPubMedPubMedCentral
7.
Lienard D, Eggermont AM, Kroon BB, et al. Isolated limb perfusion in primary and recurrent melanoma: indications and results. Semin Surg Oncol. 1998;14(3):202–09.CrossRefPubMed
8.
Moller MG, Lewis JM, Dessureault S, et al. Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. Int J Hyperthermia. 2008;24(3):275–89.CrossRefPubMed
9.
Thompson JF, Waugh RC, Saw RP, et al. Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Reg Cancer Treat. 1994;7:188–92.
10.
Kroon HM, Coventry BJ, Giles MH, et al. Australian Multicenter Study of Isolated Limb Infusion for Melanoma. Ann Surg Oncol. 2016;23(4):1096–103.CrossRefPubMed
11.
Chi Z, Li S, Sheng X, et al. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer. 2011;11:85.CrossRefPubMedPubMedCentral
12.
Muilenburg DJ, Beasley GM, Thompson ZJ, et al. Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma. Ann Surg Oncol. 2015;22(2):482–8.CrossRefPubMed
13.
Si L, Kong Y, Xu X, et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer. 2012;48(1):94–100.CrossRefPubMed
14.
Beasley GM, Petersen RP, Yoo J, et al. Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol. 2008;15(8):2195–205.CrossRefPubMed
15.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.CrossRefPubMed
16.
Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18(10):905–10.CrossRefPubMed
17.
Kroon HM, Moncrieff M, Kam PC, et al. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol. 2008;15(11):3003–13.CrossRefPubMed
18.
Brady MS, Brown K, Patel A, et al. Isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft-tissue sarcoma of the extremity: final report of a phase II clinical trial. Melanoma Res. 2009;19(2):106–11.CrossRefPubMed
19.
Kroon HM, Huismans AM, Kam PC, et al. Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review. J Surg Oncol. 2014;109(4):348–51.CrossRefPubMed
20.
Boriani F, O’Leary F, Tohill M, et al. Acral Lentiginous Melanoma—misdiagnosis, referral delay and 5 years specific survival according to site. Eur Rev Med Pharmacol Sci. 2014;18(14):1990–96.PubMed
21.
Hayward NK, Wilmott JS, Waddell N, et al. Whole-genome landscapes of major melanoma subtypes. Nature. 2017;545(7653):175–80.CrossRefPubMed
22.
Huismans AM, Kroon HM, Kam PC, et al. Does increased experience with isolated limb infusion for advanced limb melanoma influence outcome? A comparison of two treatment periods at a single institution. Ann Surg Oncol. 2011;18(7):1877–83.CrossRefPubMed
23.
Lindner P, Doubrovsky A, Kam PC, et al. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol. 2002;9(2):127–36.CrossRefPubMed
24.
Steinman J, Ariyan C, Rafferty B, et al. Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion. J Surg Oncol. 2014;109(5):405–9.CrossRefPubMed
25.
Vrouenraets BC, Nieweg OE, Kroon BB. Thirty-five years of isolated limb perfusion for melanoma: indications and results. Br J Surg. 1996;83(10):1319–28.CrossRefPubMed
26.
Kroon HM, Moncrieff M, Kam PC, et al. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol. 2009;16(5):1184–92.CrossRefPubMed
27.
Kroon HM, Lin DY, Kam PC, et al. Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma. Ann Surg Oncol. 2009;16(5):1193–201.CrossRefPubMed
28.
Chang CJ, Tai KF, Roffler S, et al. The immunization site of cytokine-secreting tumor cell vaccines influences the trafficking of tumor-specific T lymphocytes and antitumor efficacy against regional tumors. J Immunol. 2004;173(10):6025–32.CrossRefPubMed
Metadata
Title
Outcomes and Predictive Factors of Isolated Limb Infusion for Patients with In-transit Melanoma in China
Authors
Siming Li, MD
Xinan Sheng, MD
Lu Si, MD
Chuanliang Cui, MD
Yan Kong, PhD
Lili Mao, MD
Bin Lian, MD
Bixia Tang, MD
Xieqiao Yan, MD
Xuan Wang, MD
Zhihong Chi, MD
Jun Guo, MD
Publication date
01-04-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 4/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6256-x

Other articles of this Issue 4/2018

Annals of Surgical Oncology 4/2018 Go to the issue

Melanomas

Steps to Getting Your Manuscript Published in a High-Quality Medical Journal

Health Services Research and Global Oncology

Association of Delivery System Integration and Outcomes for Major Cancer Surgery

Head and Neck Oncology

A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer

Bone and Soft Tissue Sarcomas

Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas

Pancreatic Tumors

Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer

Endocrine Tumors

Cost Effectiveness of Routine Laryngoscopy in the Surgical Treatment of Differentiated Thyroid Cancer